Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI ranks Bioaffinity Technologies, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for BIAF is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BIAF included.
Follow BIAF free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
| Metric | BIAF | Rank |
|---|---|---|
| EPS | $-9.13 | – |
| Metric | BIAF | Rank |
|---|---|---|
| ROE | -402.9% | 9/10 |
| ROA | -199.3% | 11/13 |
| Operating Margin | -209.8% | 9/13 |
| Net Margin | -257.3% | 8/11 |
| EBT Margin | -257.2% | 9/13 |
| Tax Rate | -0.3% | – |
| Metric | BIAF | Rank |
|---|---|---|
| Current Ratio | 1.44x | 5/16 |
| Quick Ratio | 1.41x | 4/6 |
| D/E Ratio | 1.02x | 6/11 |
| Financial Leverage | 2.02x | 6/11 |
| Interest Coverage | -249.2x | 9/13 |
| Working Capital | $1M | 6/15 |
| Metric | BIAF | Rank |
|---|---|---|
| Operating Cash Flow | -$11M | 12/15 |
| Free Cash Flow | -$12M | 4/7 |
| Capital Spending | -$90K | 1/7 |
| FCF/Sales | -195.9% | 7/8 |
| CapEx/Sales | 1.6% | 7/8 |
| Metric | BIAF | Rank |
|---|---|---|
| Asset Turnover | 0.77x | 3/9 |
| Fixed Assets Turnover | 18.8x | 2/9 |
| Metric | BIAF | Rank |
|---|---|---|
| Total Revenue | $5M | 7/8 |
| Operating Income | -$12M | 11/15 |
| Net Income | -$15M | 9/13 |
| R&D Expense | $1M | 6/7 |
| SG&A Expense | $11M | 9/12 |
| Metric | BIAF | Rank |
|---|---|---|
| EPS Growth | -251.9% | – |
| Total Current Assets | $4M | 50.8% of assets |
| Cash & Short-term Investments | $2M | 31.9% of assets |
| Inventory | $80K | 1.0% of assets |
| Total Liabilities | $4M | 50.5% of assets |
| Short-term Debt | $2M | 22.4% of assets |
Companies classified under the same SEC industry code as Bioaffinity Technologies, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BIAF Bioaffinity Technologies, Inc. | ▼ | N/A |
| IQV Iqvia Holdings Inc. | ▼ | $43.51B |
| INCY Incyte Corp | ▼ | $21.70B |
| MEDP Medpace Holdings, Inc. | ▶ | $17.02B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.27B |
| ICLR Icon Plc | ▶ | $12.68B |
| ABSI Absci Corp | ▲ | $1.56B |
| OABI Omniab, Inc. | ▲ | $683M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $100M |
| ONMD Onemednet Corp | ▶ | $24M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BUDZ Weed, Inc. | ▶ | $3M |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
| FOXO Foxo Technologies Inc. | ▼ | N/A |
| ISPC Ispecimen Inc. | ▼ | N/A |
BIAF #BIAF--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare ...
Affinity Technologies, Inc. announced it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company's sputum-based tests in development to ...
Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.
Our AI ranks Bioaffinity Technologies, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for BIAF is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Bioaffinity Technologies, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
16 issuers in our coverage, BIAF included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.